Physician profile
David M Bear
NPI 1689643645
$512,796.09
in general payments reported to CMS, 2019-2025
88 companies · $139K in 2025
The $139K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $71K · 2021: $59K · 2022: $67K · 2023: $38K · 2024: $96K · 2025: $139K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $174K · Consulting Fee: $51K · Honoraria: $20K · Food and Beverage: $18K · Travel and Lodging: $9,429 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $173,815.25 |
| Consulting Fee | $51,274.50 |
| Honoraria | $20,198.50 |
| Food and Beverage | $18,146.18 |
| Travel and Lodging | $9,429.09 |
| Education | $294.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $245,588.94 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Abbvie INC. | $77,507.14 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Lundbeck LLC | $30,021.98 | 2019-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $24,011.46 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Eli Lilly and Company | $17,062.38 | 2020-2025 | Kisunla |
| Impel Pharmaceuticals INC. | $15,780.00 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $15,528.54 | 2021 | |
| Amgen INC. | $14,768.71 | 2019-2025 | Uplizna |
| Pfizer INC. | $14,328.11 | 2019-2025 | |
| Allergan, INC. | $11,786.78 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $10,136.80 | 2022 | |
| Axsome Therapeutics, INC. | $8,332.49 | 2023-2025 | Symbravo, Sunosi |
| Jazz Pharmaceuticals INC. | $8,246.15 | 2019-2025 | |
| Eisai INC. | $2,792.21 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,547.68 | 2019-2025 |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $1,247.31 | 2019-2025 | Gocovri |
| Sk Life Science, INC. | $1,103.01 | 2020-2025 | Xcopri |
| Biogen, INC. | $807.46 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Emd Serono, INC. | $762.11 | 2019-2025 | Mavenclad |
| Ucb, INC. | $666.04 | 2019-2025 | Nayzilam, Briviact, Zilbrysq |
| Genentech USA, INC. | $590.22 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Acorda Therapeutics, INC | $448.34 | 2020-2024 | Inbrija |
| Sunovion Pharmaceuticals INC. | $447.16 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $432.40 | 2022-2025 | Ultomiris |
| Genzyme Corporation | $407.02 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $397.38 | 2020-2025 | Firdapse, Fycompa |
| Supernus Pharmaceuticals, INC. | $365.15 | 2019-2022 | |
| Celgene Corporation | $349.02 | 2020-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $344.24 | 2019-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $318.72 | 2023-2025 | Rexulti, Nuedexta |
| Csl Behring | $307.78 | 2020-2025 | Hizentra |
| Argenx US, INC. | $304.90 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Octapharma USA, INC. | $297.57 | 2022-2025 | Panzyga |
| Adamas Pharmaceuticals, INC. | $228.19 | 2019-2021 | |
| Grifols USA, LLC | $227.73 | 2021-2025 | Gamunex-C |
| Merz Pharmaceuticals, LLC | $216.07 | 2022-2025 | Xeomin, Inbrija |
| Neurocrine Biosciences, INC. | $201.28 | 2019-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $201.04 | 2019-2025 | Hyqvia, Trintellix |
| Greenwich Biosciences, INC. | $180.91 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $180.63 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $178.79 | 2019-2025 | Rytary, Crexont |
| Merz North America, INC. | $172.81 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $152.02 | 2020-2024 | Acthar |
| Averitas Pharma INC. | $140.15 | 2024-2025 | Qutenza |
| Alnylam Pharmaceuticals INC. | $138.78 | 2019-2024 | Amvuttra |
| Merck Sharp & Dohme LLC | $137.64 | 2020-2023 | Belsomra |
| Ge Healthcare | $133.69 | 2019-2024 | |
| Horizon Therapeutics Plc | $128.05 | 2021-2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $123.05 | 2020-2024 | Cobenfy |
| Philips North America LLC | $118.72 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $116.15 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $109.43 | 2020-2025 | Wakix |
| Neurelis, INC. | $106.51 | 2020-2025 | Valtoco |
| Inspire Medical Systems, INC. | $101.97 | 2023-2025 | Inspire |
| Livanova USA, INC. | $99.94 | 2019-2021 | |
| Revance Therapeutics, INC. | $93.00 | 2024-2025 | Daxxify, Daxi |
| Kyowa Kirin, INC. | $86.03 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $85.52 | 2019 | |
| Xeris Pharmaceuticals, INC. | $83.84 | 2021-2024 | Keveyis |
| Tanabe Pharma America, INC. | $83.55 | 2021-2025 | Radicava |
| Assertio Therapeutics, INC. | $83.30 | 2019-2020 | |
| Genentech, INC. | $76.41 | 2025 | Ocrevus Zunovo |
| Astrazeneca Pharmaceuticals Lp | $75.55 | 2021-2025 | Wainua |
| Avanir Pharmaceuticals, INC. | $69.79 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
| Currax Pharmaceuticals LLC | $53.93 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $53.65 | 2022 | |
| Boston Scientific Corporation | $46.68 | 2021-2024 | Vercise |
| Medtronic, INC. | $41.81 | 2022-2024 | Activa Pc |
| Strongbridge US INC. | $39.84 | 2020 | |
| Akcea Therapeutics, INC. | $39.17 | 2020-2021 | |
| Abbott Laboratories | $33.31 | 2022-2024 | Infinity |
| Nevro Corp. | $29.64 | 2023 | Senza |
| Arbor Pharmaceuticals, INC. | $29.51 | 2019-2021 | |
| 3b Medical, INC. | $23.19 | 2023 | Luna |
| Novo Nordisk INC | $22.00 | 2019-2020 | |
| Janssen Biotech, INC. | $20.41 | 2025 | |
| Ani Pharmaceuticals, INC. | $18.51 | 2022 | |
| Sumitomo Pharma America, INC. | $16.80 | 2023 | Aptiom |
| Vertical Pharmaceuticals, LLC | $16.21 | 2019 | |
| Vanda Pharmaceuticals INC. | $15.39 | 2025 | Ponvory |
| Avion Pharmaceuticals | $15.27 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.75 | 2024 | |
| Zyla Life Sciences, INC. | $13.70 | 2020 | |
| Promius Pharma LLC | $12.63 | 2019 | |
| Medtronic USA, INC. | $12.51 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$181,340.71 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.